The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Fresh & Ready Foods, LLC, recalled a few of their ready-to-eat products, including sandwiches and other snack items, over ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $485 from $483 and keeps an Outperform rating on the shares ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO- ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

NEW YORK (AP) — Wall Street is holding near its record heights on Monday, ahead of a week likely to be dominated by updates ...